about
Biochemical, structural, and biological evaluation of tranylcypromine derivatives as inhibitors of histone demethylases LSD1 and LSD2Synthesis, stereochemical separation, and biological evaluation of selective inhibitors of human MAO-B: 1-(4-arylthiazol-2-yl)-2-(3-methylcyclohexylidene)hydrazinesPure Diastereomers of a Tranylcypromine-Based LSD1 Inhibitor: Enzyme Selectivity and In-Cell Studies.Discovery of in vitro antitubercular agents through in silico ligand-based approaches.Synthesis, biological evaluation and 3D-QSAR of 1,3,5-trisubstituted-4,5-dihydro-(1H)-pyrazole derivatives as potent and highly selective monoamine oxidase A inhibitors.Synthesis, biological evaluation and structure-activity correlation study of a series of imidazol-based compounds as Candida albicans inhibitors.Exploring the role of 2-chloro-6-fluoro substitution in 2-alkylthio-6-benzyl-5-alkylpyrimidin-4(3H)-ones: effects in HIV-1-infected cells and in HIV-1 reverse transcriptase enzymes.New indolylarylsulfones as highly potent and broad spectrum HIV-1 non-nucleoside reverse transcriptase inhibitors.Carprofen analogues as sirtuin inhibitors: enzyme and cellular studies.2-(Alkyl/aryl)amino-6-benzylpyrimidin-4(3H)-ones as inhibitors of wild-type and mutant HIV-1: enantioselectivity studies.Synthesis and antifungal activity of a new series of 2-(1H-imidazol-1-yl)-1-phenylethanol derivatives.3-Acetyl-2,5-diaryl-2,3-dihydro-1,3,4-oxadiazoles: a new scaffold for the selective inhibition of monoamine oxidase B.Modulation of cell differentiation, proliferation, and tumor growth by dihydrobenzyloxopyrimidine non-nucleoside reverse transcriptase inhibitors.3-(Phenyl-4-oxy)-5-phenyl-4,5-dihydro-(1H)-pyrazole: A fascinating molecular framework to study the enantioseparation ability of the amylose (3,5-dimethylphenylcarbamate) chiral stationary phase. Part I. Structure-enantioselectivity relationships.Novel cinnamyl hydroxyamides and 2-aminoanilides as histone deacetylase inhibitors: apoptotic induction and cytodifferentiation activity.Indolylarylsulfones bearing natural and unnatural amino acids. Discovery of potent inhibitors of HIV-1 non-nucleoside wild type and resistant mutant strains reverse transcriptase and coxsackie B4 virus.1-[(3-Aryloxy-3-aryl)propyl]-1H-imidazoles, new imidazoles with potent activity against Candida albicans and dermatophytes. Synthesis, structure-activity relationship, and molecular modeling studies.Chiral Indolylarylsulfone Non-Nucleoside Reverse Transcriptase Inhibitors as New Potent and Broad Spectrum Anti-HIV-1 Agents.Design, synthesis, biological evaluation, and molecular modeling studies of TIBO-like cyclic sulfones as non-nucleoside HIV-1 reverse transcriptase inhibitors.Inherently chiral electrodes: the tool for chiral voltammetry.Indolylarylsulfones carrying a heterocyclic tail as very potent and broad spectrum HIV-1 non-nucleoside reverse transcriptase inhibitors.Application of an immobilised amylose-based chiral stationary phase to the development of new monoamine oxidase B inhibitors.Synthesis, semipreparative HPLC separation, biological evaluation, and 3D-QSAR of hydrazothiazole derivatives as human monoamine oxidase B inhibitors.Inherently chiral macrocyclic oligothiophenes: easily accessible electrosensitive cavities with outstanding enantioselection performances.Direct HPLC enantioseparation of omeprazole and its chiral impurities: application to the determination of enantiomeric purity of esomeprazole magnesium trihydrate.A new series of flavones, thioflavones, and flavanones as selective monoamine oxidase-B inhibitors.Conformational and temperature effects on separation of stereoisomers of a C3,C4-substituted beta-lactamic cholesterol absorption inhibitor on amylose-based chiral stationary phases.Analytical and semipreparative enantiomeric separation of azole antifungal agents by high-performance liquid chromatography on polysaccharide-based chiral stationary phases. Application to in vitro biological studies.Synthesis, in vitro, and in vivo biological evaluation and molecular docking simulations of chiral alcohol and ether derivatives of the 1,5-diarylpyrrole scaffold as novel anti-inflammatory and analgesic agents.Conversion of a racemic mixture of 8-chloro-2-(2,6-difluorophenylmethyl)-2,3-dihydro-3-methyl-1,2,5-benzothiadiazepin-4(5h)-one 1,1-dioxide into a single enantiomer via a chromatographic resolution/racemization method.A chromatographic and computational study on the driving force operating in the exceptionally large enantioseparation of N-thiocarbamoyl-3-(4'-biphenyl)-5-phenyl-4,5-dihydro-(1H) pyrazole on a 4-methylbenzoate cellulose-based chiral stationary phaseSynthesis and selective inhibitory activity of 1-acetyl-3,5-diphenyl-4,5-dihydro-(1H)-pyrazole derivatives against monoamine oxidase.Enantiomers of C(5)-chiral 1-acetyl-3,5-diphenyl-4,5-dihydro-(1H)-pyrazole derivatives: Analytical and semipreparative HPLC separation, chiroptical properties, absolute configuration, and inhibitory activity against monoamine oxidase.Influence of the nature of alkyl substituents on the high-performance liquid chromatography enantioseparation and retention of new atropisomeric 1,1'-bibenzimidazole derivatives on amylose tris(3,5-dimethylphenylcarbamate) chiral stationary phase.Unusually high enantioselectivity in high-performance liquid chromatography using cellulose tris(4-methylbenzoate) as a chiral stationary phase.Semipreparative HPLC enantioseparation, chiroptical properties, and absolute configuration of two novel cyclooxygenase-2 inhibitors.Chiral HPLC separation and absolute configuration of novel S-DABO derivatives.Comparative study between the polysaccharide-based chiralcel OJ and chiralcel OD CSPSs in chromatographic enantioseparation of imidazole analogues of fluoxetine and miconazole.A rational approach to predict and modulate stereolability of chiral alpha substituted ketones.Design, synthesis, and biological activities of pyrrolylethanoneamine derivatives, a novel class of monoamine oxidases inhibitors.
P50
Q27660798-9F6D6BFB-C81B-4024-AFEF-CDA500D52199Q28290729-BB83A6D4-2853-477C-8644-E2C342D7E383Q35086759-443525C2-70DB-4D30-BDD2-B8C4414B90F2Q36033940-3A483E57-7847-439C-972A-298E0CE0B9D8Q36486172-9E7940AD-27A3-4242-9EB2-225F96E9F8CFQ38976663-FC5ACC41-D190-44F6-A918-43371D5D39D4Q38984313-8F953A7B-DFE9-4153-A4D2-161D5FE3AF5CQ39000998-336EB6A2-E5B2-4C2B-BD94-3EC79C3EFA8EQ39071971-4A7EB803-0431-48C4-8123-7F791CF70765Q39377246-6CC3B339-7AC6-42DA-9D29-3BA13FE85C2FQ39398890-4DEA8964-7E63-49B4-8C9A-E2A58D615AB2Q39503304-56E6EB60-17BE-4199-AA98-1EA60BEC62B6Q39506980-AE8EC9B3-F35E-4536-A7DF-4BE037E250FFQ39556209-2087CB49-5856-4FA7-80EF-DA385031BEA4Q39581390-66711AC0-6E96-4CD5-855C-BD1C56FB2F19Q39873922-F176D4DC-F3CE-4210-B98F-DFBB9EFDEF36Q39974996-78F32E7C-0EE5-4A8C-A05F-9D190613AF91Q40154491-B339B46C-728B-4125-8CC3-BDB237C5DEEFQ40246588-D233DE8F-50CC-43B6-A247-5775824577C8Q41047854-BFCC3A8C-517E-4752-A189-7EB49350E1A8Q42180880-EE86893C-B875-4378-91BD-B53F6EC09ADDQ42946390-CC19E929-9D07-4376-9CE8-A7C58E705936Q43004937-1C992330-226B-42FB-9AD0-C0C92BE90438Q43072946-58FC3BF5-FF58-4BE5-923D-498156A34D7AQ43118429-C9B1D5FD-165A-4D4D-8774-0EA841DF858AQ43203273-D67305D4-0D0C-4F63-A58E-2C7157284A6BQ43710960-C7C6E9BB-17A8-4D4A-B7A3-F303F57E72EDQ43873255-85800FCD-A016-47A2-BEEA-FC23B3CDF4EBQ44201078-921A7FB5-4687-4E04-A5A9-1B13265E83FBQ44401700-8DB38F56-5C41-419B-B337-DFA162AE1B28Q44586660-BFC6CE9F-60AA-4D74-BD25-9F704D21B37FQ44823674-F63F6B4F-583F-485B-8BBA-CFE4930D4F1DQ45070123-DBA971CF-4D51-47C5-8ACD-A0ACC9E35EF8Q45879351-9F96617E-CEDF-41BA-8A6B-BEB5A54B34BCQ46036543-7FDC12F1-E4E9-4F62-A771-E9FDF5FE79D0Q46075594-2A8EE166-9A05-4FE6-9740-4124623F0010Q46379717-2326ED0D-642E-47D2-A333-E49BB60BF444Q46506489-7D36B4E8-7EAA-4E78-8756-465DFC6F86DDQ46540617-A7A00FA6-9861-452A-BA94-0AD8E7003FEDQ46563149-DF29846E-70BB-438F-B284-329C72E2B6EB
P50
description
hulumtues
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Roberto Cirilli
@ast
Roberto Cirilli
@en
Roberto Cirilli
@es
Roberto Cirilli
@nl
Roberto Cirilli
@sl
type
label
Roberto Cirilli
@ast
Roberto Cirilli
@en
Roberto Cirilli
@es
Roberto Cirilli
@nl
Roberto Cirilli
@sl
prefLabel
Roberto Cirilli
@ast
Roberto Cirilli
@en
Roberto Cirilli
@es
Roberto Cirilli
@nl
Roberto Cirilli
@sl
P106
P1153
6603445261
P21
P31
P496
0000-0001-6346-1953